On Monday, October 20, Exelixis, Inc. (NASDAQ: EXEL ) reported results from its STELLAR-303 trial of zanzalintinib plus atezolizumab vs. regorafenib in metastatic colorectal cancer (mCRC). In my previous article I noted the company had already announced the trial hadScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment ...